Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.
were used. For fluoroquinolones, trovafloxacin breakpoints were used, as that agent was the only fluoroquinolone for which resistance breakpoints were provided for anaerobes. For rifampin, vancomycin, and clarithromycin, the CLSI interpretive categories for Staphylococcus aureus were used. For fusidic acid, the proposed resistance breakpoint of 2 g/ml was used (3) . Pulsed-field gel electrophoresis (PFGE) of C. difficile isolates was performed according to the method described by Fawley and Wilcox (4) , and strain relatedness was determined using the criteria of Tenover et al. (17) as previously described (10) .
In Table 1 , results are expressed as MIC 50 , MIC 90 , range, and percentage of strains resistant at the breakpoint. The isolates were uniformly susceptible to vancomycin, metronidazole, rifampin, and meropenem and resistant to bacitracin, ciprofloxacin, levofloxacin, and cefotaxime. Few isolates were resistant to piperacillin-tazobactam and fusidic acid. Resistance to clindamycin was not prevalent (14.7%). Analysis of drug cross-resistance revealed a strong association between resistance to clarithromycin and resistance to gatifloxacin and moxifloxacin.
Among the 251 isolates genotyped by PFGE, there were two major clonal strains, types NAP1 (69.3% of the isolates) and NAP2 (11.2% of the isolates). The remaining 49 isolates belonged to other PFGE patterns. Table 2 summarizes the comparative results obtained for genotype NAP1 and NAP2 strains and the other, non-NAP1 non-NAP2 strains. The NAP1 genotype strain was resistant to clarithromycin and fluoroquinolones but susceptible to clindamycin, while the NAP2 strain was resistant to clarithromycin, fluoroquinolones, and clindamycin. The remaining isolates with other PFGE patterns were mostly susceptible to gatifloxacin, moxifloxacin, clindamycin, and clarithromycin. Among the 21 historic isolates, there were 2 (9.5%) NAP1 pattern isolates, 7 (33.3%) NAP2 pattern isolates, and 12 isolates with other PFGE patterns. In contrast to the current NAP1 isolates, the two historic NAP1 isolates were resistant to ciprofloxacin (MICs, Ն32 g/ml) and levofloxacin (MICs, Ͼ32 g/ml) but susceptible to gatifloxacin and moxifloxacin, with MICs of Յ4 g/ml. Similar to the current NAP2 isolates, isolates with the NAP2 pattern were resistant to all of the fluoroquinolones and to clindamycin and azithromycin. All historic isolates were susceptible to metronidazole and vancomycin, with MIC 90 s of 0.25 g/ml and 2.0 g/ml, respectively.
Management of CDAD includes withdrawal of the predisposing antibiotic and often therapy with either metronidazole or oral vancomycin (2) . The treatment alternatives reported in the literature are diverse and include fusidic acid, rifampin, and bacitracin with reported efficacy (8) .
In this study, metronidazole and vancomycin remained highly and uniformly active in vitro. Among the current isolates, the MIC 90 s to metronidazole and vancomycin have not increased compared to those of historic isolates. However, in vitro antimicrobial susceptibility is not necessarily predictive of a successful therapeutic outcome. Recently, metronidazole treatment of CDAD has been associated with poor outcomes (12) and an increasing risk of relapse (15) , calling into question its role as the first-line agent for the treatment of CDAD. Prospective randomized trials are needed to confirm these observations (6) .
Fusidic acid and rifampin, two other potentially useful agents for the treatment of CDAD, were very active in vitro. However, bacitracin showed no activity against any of the isolates. As previously observed, the majority of strains were resistant to cefotaxime but susceptible to meropenem and piperacillin-tazobactam (5, 7). Isolates were also highly resistant to clarithromycin and the fluoroquinolones, findings similar to those recently reported in the United Kingdom (7).
The two predominant genotypes were highly resistant to clarithromycin and the fluoroquinolones but differed markedly in their susceptibilities to clindamycin. There was no crossresistance between clindamycin and clarithromycin. The NAP1 strain was susceptible to clindamycin, while the second most commonly identified genotype, NAP2, was highly resistant to this agent. In contrast to results recently reported in the United States, where clindamycin-resistant clones have been associated with multihospital outbreaks of CDAD (11), our major epidemic strain was susceptible to clindamycin, a finding also observed in the United Kingdom strains (7).
Among 21 historical isolates, two NAP1 isolates were identified. These isolates were susceptible to gatifloxacin and moxifloxacin, in contrast to the current NAP1 isolates. These results corroborate those obtained in the United States when NAP1 contemporary isolates were compared to historic isolates predating 2001.
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